Session I: The Need for New Antimicrobial Agents
- The Need for New Antibiotics
Hartmut Lode, DE - The Need for New Antifungal Agents
Frank C. Odds, UK - Disruption of protein-protein interactions as a novel antiviral strategy
Giorgio Palù and Arianna Loregian, IT - The Need For New Anti-Parasitic Drugs
Peter L Chiodini, UK
Session II: The Regulatory Situation
- Industry and Academia as Research Partners
Francis A. Waldvogel, CH - Can Pharmacokinetics/Pharmacodynamics Replace Clinical Trials?
Johan W Mouton, NL - EMEA and CPMP – hurdles or opportunities?
Bo Aronsson, EMEA, UK
Session III: Improving the Future
- Genomic and functional approaches to identify novel antibiotics that block virulence
Staffan Normark, SE - Role of the Biotech Industry
Goran Ando, Celltech Group PLC - Can We Improve Clinical Trial Design
Roger Finch, UK - Big and Small Pharma in the Development of Infectious Disease Treatment
Barbara Hampel - The Orphan Drug Option
Jordi Llinares Garcia, EMEA - Immunotherapy of Infectious Diseases
Jaap T. van Dissel, NL
